Stay updated with breaking news from Nasdaq Kron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 597,700 shares, a drop of 74.9% from the January 15th total of 2,380,000 shares. Currently, 1.6% of the shares of the stock are sold short. Based […]
Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) COO Barbara Kosacz sold 10,676 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $1.18, for a total value of $12,597.68. Following the transaction, the chief operating officer now owns 928,966 shares of the company’s […]
Kronos Bio (NASDAQ:KRON – Free Report) had its price target cut by HC Wainwright from $9.00 to $2.50 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. Separately, Piper Sandler dropped their price objective on Kronos Bio from $7.00 to $6.00 and set an […]
Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) insider Christopher Dinsmore sold 10,032 shares of Kronos Bio stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $1.30, for a total transaction of $13,041.60. Following the completion of the transaction, the insider now owns 268,335 shares in the […]
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed...